The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
- Conditions
- Locally Advanced Non-small Cell Lung Cancer
- Interventions
- Radiation: concurrent or sequential chemoradiotherapyDrug: Immunotherapy
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-03-01
- Target Recruit Count
- 200
- Registration Number
- NCT06287320
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
HA-WBRT-SIB for Brain Metastasis of Lung Cancer
- Conditions
- Simultaneous Integrated BoostLung NeoplasmBrain MetastasesHippocampal AvoidanceCognitive Function
- Interventions
- Radiation: HA-WBRT-SIB
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-03-01
- Target Recruit Count
- 40
- Registration Number
- NCT06289023
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciecnces and Peking Union Medical College, Beijing, Beijing, China
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
- Conditions
- Prositron Emission TomographyMedullary Thyroid CancerSurgeryFibroblast Activation Protein Inhibitor
- Interventions
- Procedure: Surgery
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Target Recruit Count
- 50
- Registration Number
- NCT06277180
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
- Conditions
- Non Small Cell Lung CancerLung AdenocarcinomaSmall-cell Lung CancerLung CancerLung Squamous Cell Carcinoma
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-16
- Target Recruit Count
- 60000
- Registration Number
- NCT06255197
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Clinical Trial for Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreas Cancer
- Interventions
- Drug: LTC004 + MIL-97Drug: LTC004 + MIL-97+chemotherapy
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-23
- Target Recruit Count
- 26
- Registration Number
- NCT06255912
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 51
- Registration Number
- NCT06245824
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
- Conditions
- Hepatocellular CarcinomaRadiotherapyTislelizumabTumor Thrombosis
- Interventions
- Radiation: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Target Recruit Count
- 30
- Registration Number
- NCT06233981
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciecnces and Peking Union Medical College, Beijing, China
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
- Conditions
- Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-01-29
- Target Recruit Count
- 182
- Registration Number
- NCT06229067
Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules
- Conditions
- Adenocarcinoma of Lung
- Interventions
- Diagnostic Test: Mass spectrometry-based proteomics
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Target Recruit Count
- 220
- Registration Number
- NCT06215885
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
- Conditions
- Narrow MarginRadiotherapyHepatocellular Carcinoma
- Interventions
- Radiation: Adjuvant SIB radiotherapy
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 100
- Registration Number
- NCT06205472
- Locations
- 🇨🇳
Bo Chen, Beijing, China